A Trend Towards Gammaretrovirus In Cell & Gene Therapy

As we enter a new era set to be dominated by cell and gene therapies (C& GTs), increasing numbers of developers are driving towards the use of gammaretrovirus (also referred to as retrovirus) as tools in their product development. In this blog, we examine the reasons behind the rising popularity of retroviral vectors amongst those in the biopharma space – from improvements in safety to the advantages offered in scalability. For a more in-depth analysis of the changing role of retroviral vectors in C& GTs, download the “Gammaretrovirus: Overcoming development and manufacturing challenges” whitepaper.

In the past two decades, once unimaginable possibilities achievable by therapeutics started to become a reality as a result of increasing advancements in the capabilities of C& GTs. The previously limited treatment options for diseases and disorders caused by genetic abnormalities – often due to missing or mutated genes – are now expanding, with C& GTs offering the potential for long-term benefits.

This article dives into three areas that are driving the trend towards a preference for retroviral vectors.